• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α-突触核蛋白 H50Q,帕金森病的一种新型致病性突变。

Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease.

机构信息

Department of Medicine (Neurology), Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Mov Disord. 2013 Jun;28(6):811-3. doi: 10.1002/mds.25421. Epub 2013 Mar 1.

DOI:10.1002/mds.25421
PMID:23457019
Abstract

BACKGROUND

Alpha-synuclein plays a central role in the pathophysiology of Parkinson's disease. Three missense mutations in SNCA, the gene encoding alpha-synuclein, as well as genomic multiplications have been identified as causes for autosomal-dominantly inherited Parkinsonism.

METHODS

Here, we describe a novel missense mutation in exon 4 of SNCA encoding a H50Q substitution in a patient with dopa-responsive Parkinson's disease with a family history of parkinsonism and dementia.

RESULTS

The variant was not observed in public databases or identified in unrelated subjects.

CONCLUSIONS

The substitution's evolutionary conservation and protein modeling provide additional support for pathogenicity as the amino acid perturbs the same amphipathic alpha helical structure as the previously described pathogenic mutations.

摘要

背景

α-突触核蛋白在帕金森病的病理生理学中起核心作用。SNCA 基因(编码α-突触核蛋白)的三个错义突变以及基因组的多次倍增已被确定为常染色体显性遗传帕金森病的原因。

方法

在这里,我们描述了一位具有家族性帕金森病和痴呆病史的多巴反应性帕金森病患者的 SNCA 外显子 4 中的一个新错义突变,该突变导致 H50Q 取代。

结果

该变体未在公共数据库中观察到,也未在无关个体中发现。

结论

该取代的进化保守性和蛋白质建模为其致病性提供了额外的支持,因为该氨基酸会扰乱与先前描述的致病性突变相同的两亲性α螺旋结构。

相似文献

1
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease.α-突触核蛋白 H50Q,帕金森病的一种新型致病性突变。
Mov Disord. 2013 Jun;28(6):811-3. doi: 10.1002/mds.25421. Epub 2013 Mar 1.
2
Parkinson disease: α-synuclein mutational screening and new clinical insight into the p.E46K mutation.帕金森病:α-突触核蛋白突变筛查及对p.E46K突变的新临床见解。
Parkinsonism Relat Disord. 2015 Jun;21(6):586-9. doi: 10.1016/j.parkreldis.2015.03.011. Epub 2015 Mar 14.
3
Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.H50Q和G51D 突触核蛋白(SNCA)突变对α-突触核蛋白聚集的不同影响。
J Neurochem. 2014 Dec;131(6):859-67. doi: 10.1111/jnc.12806. Epub 2014 Jul 21.
4
[Relationship between alpha-synuclein and Parkinson's disease].[α-突触核蛋白与帕金森病的关系]
Brain Nerve. 2007 Aug;59(8):825-30.
5
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.与α-突触核蛋白(SNCA)重复及H50Q突变相比,G51D SNCA突变病例的独特临床和神经病理学特征。
Mol Neurodegener. 2015 Aug 27;10:41. doi: 10.1186/s13024-015-0038-3.
6
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.帕金森病中α-突触核蛋白基因重复的临床异质性。
Ann Neurol. 2006 Feb;59(2):298-309. doi: 10.1002/ana.20753.
7
Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus?伴有帕金森病、痴呆或进行性肌阵挛的α-突触核蛋白倍增?
Parkinsonism Relat Disord. 2009 Jun;15(5):390-2. doi: 10.1016/j.parkreldis.2008.08.002. Epub 2008 Sep 27.
8
Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease.常染色体显性帕金森病中的α-突触核蛋白错义突变和倍增突变。
Neurosci Lett. 2004 Aug 26;367(1):97-100. doi: 10.1016/j.neulet.2004.05.100.
9
The many faces of alpha-synuclein mutations.α-突触核蛋白突变的多态性。
Mov Disord. 2013 Jun;28(6):697-701. doi: 10.1002/mds.25499. Epub 2013 May 14.
10
The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro.帕金森病相关的 H50Q 突变加速了α-突触核蛋白的体外聚集。
Biochemistry. 2013 Oct 8;52(40):6925-7. doi: 10.1021/bi400999d. Epub 2013 Sep 23.

引用本文的文献

1
Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein.路易体痴呆:探索淀粉样β蛋白、tau蛋白和α-突触核蛋白的生物标志物及致病相互作用
Mol Neurodegener. 2025 Aug 12;20(1):90. doi: 10.1186/s13024-025-00879-0.
2
Expression of human A53T alpha-synuclein without endogenous rat alpha-synuclein fails to elicit Parkinson's disease-related phenotypes in a novel humanized rat model.在一种新型人源化大鼠模型中,缺乏内源性大鼠α-突触核蛋白的情况下,人A53Tα-突触核蛋白的表达未能引发帕金森病相关表型。
PLoS One. 2025 Aug 8;20(8):e0329823. doi: 10.1371/journal.pone.0329823. eCollection 2025.
3
Cognitive Decline in Parkinsonism: From Clinical Phenotypes to the Genetic Background.
帕金森病中的认知衰退:从临床表型到遗传背景
Biomedicines. 2025 Jul 2;13(7):1624. doi: 10.3390/biomedicines13071624.
4
The Yeast Parkinson's Disease Model Exhibits An Increase in Peroxisome Number Independent of the Division Proteins Vps1 and Dnm1.酵母帕金森病模型显示过氧化物酶体数量增加,且与分裂蛋白Vps1和Dnm1无关。
Mol Neurobiol. 2025 Jul 24. doi: 10.1007/s12035-025-05236-2.
5
Exploring α-Syn's Functions Through Ablation Models: Physiological and Pathological Implications.通过基因敲除模型探索α-突触核蛋白的功能:生理和病理意义
Cell Mol Neurobiol. 2025 May 19;45(1):44. doi: 10.1007/s10571-025-01560-2.
6
Alpha-synuclein pathology and Parkinson's disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches.α-突触核蛋白病理学与帕金森病相关嗅觉功能障碍:临床前模型与治疗方法的最新进展
Mamm Genome. 2025 Apr 28. doi: 10.1007/s00335-025-10128-w.
7
Development of In Vitro Parkinson's Disease Model Mediated by MPP+ and α-Synuclein Using Wharton's Jelly Mesenchymal Stem Cells.利用沃顿胶间充质干细胞建立由MPP +和α-突触核蛋白介导的体外帕金森病模型
CNS Neurosci Ther. 2025 Apr;31(4):e70299. doi: 10.1111/cns.70299.
8
α-Synuclein Pathology Spreads in a Midbrain-Hindbrain Assembloid Model.α-突触核蛋白病理学在中脑-后脑类器官模型中扩散。
Adv Sci (Weinh). 2025 May;12(20):e2409040. doi: 10.1002/advs.202409040. Epub 2025 Apr 17.
9
Local Ionic Conditions Modulate the Aggregation Propensity and Influence the Structural Polymorphism of α-Synuclein.局部离子条件调节α-突触核蛋白的聚集倾向并影响其结构多态性。
J Am Chem Soc. 2025 Apr 23;147(16):13131-13145. doi: 10.1021/jacs.4c13473. Epub 2025 Apr 10.
10
Limitations and Applications of Rodent Models in Tauopathy and Synucleinopathy Research.啮齿动物模型在tau蛋白病和α-突触核蛋白病研究中的局限性与应用
J Neurochem. 2025 Mar;169(3):e70021. doi: 10.1111/jnc.70021.